D. Boral Capital Has Lowered Expectations for FibroBiologics (NASDAQ:FBLG) Stock Price

FibroBiologics (NASDAQ:FBLG) had its target price decreased by D. Boral Capital from $15.00 to $7.00 in a research note issued to investors on Wednesday,Benzinga reports. The firm presently has a “buy” rating on the stock.

Other equities analysts have also issued reports about the company. HC Wainwright reaffirmed a “buy” rating and issued a $5.00 target price on shares of FibroBiologics in a research report on Friday, January 2nd. Weiss Ratings reissued a “sell (e+)” rating on shares of FibroBiologics in a research report on Thursday, January 22nd. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $6.00.

FibroBiologics Trading Down 1.6%

NASDAQ:FBLG traded down $0.00 during trading hours on Wednesday, hitting $0.26. The stock had a trading volume of 706,946 shares, compared to its average volume of 1,321,117. The business has a 50 day simple moving average of $0.29 and a two-hundred day simple moving average of $0.39. FibroBiologics has a 1-year low of $0.22 and a 1-year high of $1.53. The company has a market cap of $17.51 million, a PE ratio of -0.55 and a beta of -0.60.

FibroBiologics (NASDAQ:FBLG) last announced its earnings results on Tuesday, February 24th. The company reported ($0.03) earnings per share for the quarter, beating the consensus estimate of ($0.09) by $0.06. Research analysts expect that FibroBiologics will post -0.53 EPS for the current fiscal year.

Insider Transactions at FibroBiologics

In related news, General Counsel Ruben A. Garcia bought 140,000 shares of the stock in a transaction dated Thursday, December 11th. The stock was bought at an average cost of $0.34 per share, with a total value of $47,600.00. Following the completion of the acquisition, the general counsel owned 140,000 shares of the company’s stock, valued at $47,600. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 13.00% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On FibroBiologics

Several large investors have recently made changes to their positions in the company. Yorkville Advisors Global LP bought a new position in shares of FibroBiologics in the third quarter worth $278,000. Landscape Capital Management L.L.C. acquired a new position in shares of FibroBiologics in the 3rd quarter worth approximately $191,000. Geode Capital Management LLC increased its holdings in shares of FibroBiologics by 20.7% in the fourth quarter. Geode Capital Management LLC now owns 348,761 shares of the company’s stock valued at $78,000 after buying an additional 59,813 shares in the last quarter. Cascade Financial Partners LLC grew its holdings in shares of FibroBiologics by 11.7% in the 2nd quarter. Cascade Financial Partners LLC now owns 290,581 shares of the company’s stock worth $181,000 after acquiring an additional 30,500 shares during the last quarter. Finally, Renaissance Technologies LLC raised its position in shares of FibroBiologics by 287.3% during the fourth quarter. Renaissance Technologies LLC now owns 231,600 shares of the company’s stock worth $52,000 after purchasing an additional 171,800 shares during the period.

FibroBiologics Company Profile

FibroBiologics, Inc operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics, Inc was incorporated in 2021 and is based in Houston, Texas.